Data from the RIDE and RISE trials showed ranibizumab-treated patients with diabetic macular edema showed lower levels of disease severity that were maintained between 24 and 36 months compared with no change in severity levels for those who received sham treatment. "These data derived from two large randomized trials of ranibizumab for diabetic macular edema provide strong evidence that ranibizumab is effective in reducing diabetic retinopathy severity level," Dr. Michael S. Ip reported at the Retina Subspecialty Day.